Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biden’s Second ‘Moonshot’: A National Subscription Model To Eliminate Hep C

Executive Summary

A federal plan that would provide a lump sum to drug makers to increase hepatitis C treatment, building on subscription models used in Louisiana and Washington state, was previewed by Francis Collins, former NIH director and current special advisor to President Biden.

You may also be interested in...

Medicaid Coverage For PrEP Without Restrictions, Cost Sharing Backed By President’s Budget

Legislation could facilitate faster access without cost sharing or restrictions for new HIV pre-exposure prophylaxis. The White House said its budget proposal to expand Medicare price negotiation would save $160bn more than the Inflation Reduction Act's existing negotiation provisions.

Cancer Moonshot Round 2 Focuses On Screening; Pharma To Participate In New Summit

The initial moonshot aimed to increase cancer research while the reboot seeks to boost screenings to reduce death rate. New cancer cabinet mirrors previous task force. Biopharmaceutical companies are to participate in summit to highlight new commitments.

Louisiana Subscription Contract For Generic Epclusa About Access, Not Discounts

Innovative purchasing model is not designed to solve the problem of high drug costs, experts point out during a recent discussion at the Brookings Institution.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts